All articles tagged with #retatrutide
Some individuals are using unapproved 'GLP-3' drugs like retatrutide from the black market for dramatic weight loss, risking unknown side effects and contamination, as these drugs are still in clinical trials and not FDA-approved, highlighting concerns over safety and regulation.
Retatrutide, an experimental weight-loss drug developed by Eli Lilly, is gaining popularity among fitness enthusiasts and bodybuilders through unofficial online channels before its official FDA approval, raising concerns about safety, regulation, and the unregulated market for research chemicals.
A phase 2 trial of retatrutide, a triple-hormone-receptor agonist, found that participants experienced significant reductions in body weight at week 48, with variability depending on the dose and the heterogeneity of obesity. Women had greater weight reductions than men, and those with a BMI of 35 or higher had greater weight reductions than those with a lower BMI. At week 48, a weight reduction of 5% or more occurred in 92% of participants who received 4 mg of retatrutide, compared to 27% of those who received placebo. Gastrointestinal symptoms were the most common adverse effects, mostly mild to moderate in severity. Further research is needed to investigate the efficacy and safety of retatrutide in treating obesity.
Eli Lilly's experimental drug, retatrutide, has shown the greatest weight loss yet in a mid-stage trial, with patients experiencing a 24.2% reduction in weight. If successful in larger Phase 3 trials, the drug could position Lilly as a leader in the race to provide effective obesity treatments. However, the U.K.'s cost-effectiveness agency has rejected Eli Lilly's Mounjaro as a treatment for type 2 diabetes, citing the need for more evidence on clinical benefits and cost effectiveness. Mounjaro is expected to gain regulatory approval for obesity later this year and is part of a group of medications showing significant weight-loss results.
Eli Lilly's experimental drug, retatrutide, which targets three hormones, led to 24.2% weight loss in a mid-stage trial, the greatest amount seen yet with an obesity drug. If the weekly injectable drug succeeds in larger Phase 3 trials, it could propel Lilly ahead of competitors in the heated race to supply the most effective obesity treatments.